<?xml version="1.0" encoding="UTF-8"?>
<p>Coronaviruses gain access to the body via the respiratory tract and it has recently been shown that nasal goblet cells, type II pneumocytes and ileal enterocytes all possess the necessary combination of ACE2 and TMPRSS2 for viral entry to be successful (
 <xref rid="B31" ref-type="bibr">31</xref>, 
 <xref rid="B37" ref-type="bibr">37</xref>). HCoV-NL63 binds to human airway epithelial cells 
 <italic>in vitro</italic> (
 <xref rid="B38" ref-type="bibr">38</xref>). In the lung, ACE2 is widely distributed throughout the bronchial and pulmonary epithelium and the pulmonary capillaries (
 <xref rid="B39" ref-type="bibr">39</xref>). ACE2 protects the lung from the pro-inflammatory and pro-fibrotic actions of circulating Ang II by metabolizing Ang II to Angâ€“(1-7), which, acting via the MasR, inhibits Ang II-AT
 <sub>1</sub>R pro-inflammatory pathways [
 <xref ref-type="fig" rid="F1">Figure 1A</xref>, (
 <xref rid="B4" ref-type="bibr">4</xref>)].
</p>
